<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456948</url>
  </required_header>
  <id_info>
    <org_study_id>01EE1401F</org_study_id>
    <nct_id>NCT02456948</nct_id>
  </id_info>
  <brief_title>Adjunct Minocyline in Treatment-resistant Depression</brief_title>
  <acronym>Mino-TRD</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Unipolar Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the antidepressant efficacy of minocycline as an adjunct to an
      antidepressant standard treatment (AD-ST), for patients with unipolar major depressive
      disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, multicenter proof-of-principle trial
      of adjunctive minocycline for patients with unipolar major depressive disorder (MDD). The
      study tests the antidepressant efficacy of minocycline as an adjunct to an antidepressant
      standard treatment (AD-ST), for patients with unipolar major depressive disorder (MDD). The
      respective AD, for which non-response has been documented, must be on a stable regimen for at
      least 14 days prior to inclusion. AD-ST will then be continued throughout the trial. Trial
      medication is adjunct oral minocycline 200 mg/day or placebo. Response to treatment will be
      measured via the Montgomery-Asberg Depression Rating Scale (MADRS). The total study duration
      for each patient will be 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response as per MADRS (Montgomery-Åsberg Depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission as per MADRS (Montgomery-Åsberg Depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-D-17-Scale (17-item Hamilton Depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI-Scale (Beck Depression Inventory, Self Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-Scale (Clinical Global Impressions Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCL-90-R (Symptom Checklist 90-R, Self Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic changes in patient-specific peripheral blood-derived monocytic cells</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein levels of various inflammation-associated markers in patient sera</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline and standard antidepressant treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and standard antidepressant treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>6 weeks 200mg/day Minocycline add-on</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Solodyn</other_name>
    <other_name>Minocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 weeks Placebo add-on</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pills, mimics Minocycline tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  male or female

          -  between age 18 and 75

          -  BMI between 18 and 40 inclusive

          -  Non-lactating, non-pregnant females of child-bearing potential must be willing to use
             an effective contraceptive method

          -  All participants must fulfil diagnostic criteria of moderate or severe MDD according
             to the DSM-5.

          -  HAMD-17 score of at least 16 points at baseline and a

          -  CGI-S score of at least 4.

          -  AD-ST must have been administered at a sufficient dose for at least 6 weeks in the
             current episode and at a

          -  stable regimen for at least 14 days prior to baseline.

          -  Dose and duration of AD-ST must be verifiable

        Exclusion Criteria:

          -  prevalence of neurodegenerative disorder

          -  prevalence of any neurological disorder that caused the depressive symptoms

          -  prevalence of any severe, unstable general medical condition, including chronic
             inflammatory disease such as rheumatoid arthritis or inflammatory bowel disease

          -  prevalence of any other psychiatric disorder that better explains the presence of
             depressive symptoms

          -  Improvement by more than 50% in HAMD-17 score during the last 14 days prior to
             baseline

          -  pregnant or nursing women will not be allowed.

          -  substance or alcohol abuse within past 6 months or positive urine drug screening

          -  abnormal thyroid function (euthyroid at presentation), liver or kidney dysfunction

          -  history of autoimmune disease (except Hashimotos thyroiditis)

          -  clinically significant laboratory abnormalities (outside normal ranges)

          -  current medication with anti-inflammatory substances (NSAIDs, corticosteroids)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabella Heuser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair: Department of Psychiatry Charité - Campus Benjamn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heidelberg University Hospital, Department of Psychiatry</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Universitiy Hospital</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, LMU Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Planck Institute of Psychiatry</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Universitiy Hospital</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Charité - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Isabella Heuser</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>treatment resistant depression</keyword>
  <keyword>inflammation</keyword>
  <keyword>microglia</keyword>
  <keyword>minocycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

